SCHEMBL2478152

SCHEMBL2478152

CN(C)c1cccc(NC(=O)N(CCCN2CCOCC2)Cc2ccc(C(=O)Nc3ccccc3N)cc2)c1

nearest known ligand 0.55

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
HDAC1 Q13547 5/20 0.55
HDAC6 Q9UBN7 2/20 0.55
CASR P41180 2/20 0.54
TSHR P16473 3/20 0.52
MAPT P10636 2/20 0.51
HSD17B10 Q99714 1/20 0.51
EPHX2 P34913 1/20 0.49
ALDH1A1 P00352 4/20 0.48
LMNA P02545 2/20 0.48
GAA P10253 1/20 0.48
THRB P10828 1/20 0.48
MAPK1 P28482 1/20 0.48
HDAC3 O15379 2/20 0.48
HDAC2 Q92769 2/20 0.48
NCOR2 Q9Y618 1/20 0.48
POLB P06746 1/20 0.47
OPRM1 P35372 1/20 0.47
OPRD1 P41143 1/20 0.47
MEN1 O00255 1/20 0.47
KMT2A Q03164 1/20 0.47

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL2470965 0.92 OPRM1 (0.53) HDAC1HDAC6TSHRMAPTHSD17B10
SCHEMBL2473883 0.89 TSHR (0.57) HDAC1CASRTSHRMAPTHSD17B10
SCHEMBL2497298 0.88 HDAC1 (0.52) HDAC1HDAC6CASRTSHRMAPT
SCHEMBL2476750 0.87 USP2 (0.54) HDAC1CASRTSHRMAPTHSD17B10
SCHEMBL2476586 0.87 HSD17B10 (0.55) HDAC1HDAC6TSHRMAPTHSD17B10
SCHEMBL2477045 0.87 POLB (0.51) HDAC1HDAC6CASRTSHRMAPT
SCHEMBL2477106 0.87 OPRM1 (0.54) HDAC1HDAC6TSHRMAPTHSD17B10
SCHEMBL2475852 0.86 OPRM1 (0.53) HDAC1HDAC6TSHRMAPTHSD17B10
SCHEMBL2473792 0.86 ALDH1A1 (0.54) HDAC1TSHRMAPTHSD17B10ALDH1A1
SCHEMBL2473980 0.86 ALDH1A1 (0.54) HDAC1TSHRMAPTHSD17B10ALDH1A1

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 9 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-8076332-B2 N- (2-aminophenyl) benzamide derivative having urea structure SANTEN PHARMACEUTICAL CO., LTD. (JP) 2011-12-13 US disclosed
US-8076332-B2 N- (2-aminophenyl) benzamide derivative having urea structure SANTEN PHARMACEUTICAL CO., LTD. (JP) 2011-12-13 US disclosed
US-8076332-B2 N- (2-aminophenyl) benzamide derivative having urea structure SANTEN PHARMACEUTICAL CO., LTD. (JP) 2011-12-13 US disclosed
EP-2107052-B1 NOVEL N-(2-AMINOPHENYL)BENZAMIDE DERIVATIVE HAVING AN UREA STRUCTURE SANTEN PHARMACEUTICAL CO LTD (JP) 2011-10-12 EP disclosed
US-20090306077-A1 NOVEL N- (2-AMINOPHENYL) BENZAMIDE DERIVATIVE HAVING UREA STRUCTURE SANTEN PHARMACEUTICAL CO., LTD. (JP) 2009-12-10 US disclosed
US-20090306077-A1 NOVEL N- (2-AMINOPHENYL) BENZAMIDE DERIVATIVE HAVING UREA STRUCTURE SANTEN PHARMACEUTICAL CO., LTD. (JP) 2009-12-10 US disclosed
US-20090306077-A1 NOVEL N- (2-AMINOPHENYL) BENZAMIDE DERIVATIVE HAVING UREA STRUCTURE SANTEN PHARMACEUTICAL CO., LTD. (JP) 2009-12-10 US disclosed
EP-2107052-A1 NOVEL N-(2-AMINOPHENYL)BENZAMIDE DERIVATIVE HAVING AN UREA STRUCTURE Santen Pharmaceutical Co., Ltd (JP) 2009-10-07 EP disclosed
EP-2107052-A1 NOVEL N-(2-AMINOPHENYL)BENZAMIDE DERIVATIVE HAVING AN UREA STRUCTURE Santen Pharmaceutical Co., Ltd (JP) 2009-10-07 EP disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20090306077-A1 NOVEL N- (2-AMINOPHENYL) BENZAMIDE DERIVATIVE HAVING UREA STRUCTURE UACA, SLC14A1, ARG2 HDAC1 200/4885HDAC6 363/4885CASR 3264/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.